Uveitis-Pipeline Review, H1 2017

Uveitis-Pipeline Review, H1 2017


  • Products Id :- GMDHC9214IDB
  • |
  • Pages: 186
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Uveitis-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Uveitis-Pipeline Review, H1 2017, provides an overview of the Uveitis (Ophthalmology) pipeline landscape.

Uveitis is swelling and irritation of the uvea, the middle layer of the eye. Uveitis can affect one or both eyes. Uveitis can be caused by autoimmune disorders such as rheumatoid arthritis or ankylosing spondylitis, infection, or exposure to toxins. Symptoms include blurred vision, dark, floating spots in the vision, eye pain, redness of the eye and sensitivity to light. The predisposing factors include having an infection, an autoimmune or inflammatory disorder and history of eye injury. Treatment includes steroid eye drops, anti-inflammatory and antibiotic or antiviral medication.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Uveitis-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Uveitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Uveitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Uveitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 5, 8, 5, 2, 29, 5 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Uveitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Uveitis (Ophthalmology).

The pipeline guide reviews pipeline therapeutics for Uveitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Uveitis (Ophthalmology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Uveitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Uveitis (Ophthalmology)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Uveitis (Ophthalmology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Uveitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Uveitis-Overview 8

Uveitis-Therapeutics Development 9

Pipeline Overview 9

Pipeline by Companies 10

Pipeline by Universities/Institutes 14

Products under Development by Companies 15

Products under Development by Universities/Institutes 19

Uveitis-Therapeutics Assessment 20

Assessment by Target 20

Assessment by Mechanism of Action 23

Assessment by Route of Administration 26

Assessment by Molecule Type 28

Uveitis-Companies Involved in Therapeutics Development 30

2-BBB Medicines BV 30

Aciont Inc 30

Aldeyra Therapeutics Inc 31

Apitope International NV 31

Astellas Pharma Inc 32

Bionomics Ltd 32

Bristol-Myers Squibb Company 33

Can-Fite BioPharma Ltd 33

Clearside BioMedical Inc 34

Coherus BioSciences Inc 34

Elasmogen Ltd 35

Endocyte Inc 35

Enzo Biochem Inc 36

EyeGate Pharmaceuticals Inc 36

Eyevensys SAS 37

F. Hoffmann-La Roche Ltd 37

HanAll Biopharma Co Ltd 38

Icon Bioscience Inc 38

Idera Pharmaceuticals Inc 39

InnoMedica Holding AG 39

KPI Therapeutics Inc 40

Midatech Pharma Plc 40

Mitotech SA 41

Nemus Bioscience Inc 41

Neuroptis Biotech 42

Novartis AG 42

Oculis ehf 43

OncoNOx ApS 43

Orchid Pharma Ltd 44

OSE Immunotherapeutics 44

Palatin Technologies Inc 45

Panacea Biotec Ltd 45

Panoptes Pharma GesmbH 46

Pfizer Inc 46

pSivida Corp 47

Re-Pharm Ltd 47

Regeneron Pharmaceuticals Inc 48

Sandoz International GmbH 48

Santen Pharmaceutical Co Ltd 49

SynDevRx Inc 49

TxCell SA 50

Uveitis-Drug Profiles 51

2B-3201-Drug Profile 51

abatacept-Drug Profile 53

adalimumab biosimilar-Drug Profile 60

adalimumab biosimilar-Drug Profile 61

adalimumab biosimilar-Drug Profile 63

adalimumab biosimilar-Drug Profile 64

ADX-102-Drug Profile 65

Antisense Oligonucleotide to Inhibit NLRP3 for Uveitis, Cystitis and Inflammatory Disorders-Drug Profile 70

Antisense RNAi Oligonucleotide to Inhibit ProRenin Receptor for Uveitis and Diabetic Retinopathy-Drug Profile 71

ANV-103-Drug Profile 72

ATXUV-1-Drug Profile 73

B27-PD-Drug Profile 74

BNC-164-Drug Profile 75

celecoxib-Drug Profile 76

Col-Treg-Drug Profile 79

CVX-001-Drug Profile 81

cyclosporine SR-Drug Profile 82

dalazatide-Drug Profile 83

dexamethasone acetate-Drug Profile 88

dexamethasone acetate-Drug Profile 93

dexamethasone acetate-Drug Profile 95

dexamethasone sodium phosphate-Drug Profile 96

Drug for Chronic Uveitis-Drug Profile 98

Drugs to Inhibit Aldose Reductase for Immunology, Ophthalmology, Infectious Disease, Metabolic and Respiratory Disorders-Drug Profile 99

EBI-031-Drug Profile 100

EC-1669-Drug Profile 101

ELN-21-Drug Profile 102

ELN-22-Drug Profile 103

EYS-606-Drug Profile 104

fluocinolone acetonide SR-Drug Profile 105

FR-104-Drug Profile 113

Gene Therapy for Dry Age-Related Macular Degeneration and Uveitis-Drug Profile 116

HL-036-Drug Profile 117

HO-10-Drug Profile 118

IVMED-10-Drug Profile 119

IVMED-20-Drug Profile 120

KPI-190-Drug Profile 121

latanoprost SR-Drug Profile 122

LME-636-Drug Profile 123

lodamin-Drug Profile 124

methotrexate-Drug Profile 125

NB-2222-Drug Profile 126

NOP-3-Drug Profile 127

OX-1001-Drug Profile 128

piclidenoson-Drug Profile 129

PL-8177-Drug Profile 138

plastoquinone decyl triphenylphosphonium bromide-Drug Profile 139

PP-001-Drug Profile 141

PPL-003-Drug Profile 143

RP-0217-Drug Profile 145

sarilumab-Drug Profile 146

sirolimus-Drug Profile 153

Small Molecule to Inhibit PDE4B and TNF Alpha for Asthma, COPD and Uveitis-Drug Profile 156

Small Molecules for Posterior Uveitis-Drug Profile 157

Small Molecules to Inhibit 5-Lipoxygenase for Uveitis-Drug Profile 158

Small Molecules to Inhibit TYK2 for Psoriasis and Uveitis-Drug Profile 159

Stem Cell Therapy for Autoimmune Diseases-Drug Profile 160

tesidolumab-Drug Profile 162

triamcinolone acetonide-Drug Profile 164

Uveitis-Dormant Projects 170

Uveitis-Discontinued Products 173

Uveitis-Product Development Milestones 174

Featured News & Press Releases 174

Appendix 181

Methodology 181

Coverage 181

Secondary Research 181

Primary Research 181

Expert Panel Validation 181

Contact Us 181

Disclaimer 182

List of Figures

Number of Products under Development for Uveitis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

List of Tables

Number of Products under Development for Uveitis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Uveitis-Pipeline by 2-BBB Medicines BV, H1 2017

Uveitis-Pipeline by Aciont Inc, H1 2017

Uveitis-Pipeline by Aldeyra Therapeutics Inc, H1 2017

Uveitis-Pipeline by Apitope International NV, H1 2017

Uveitis-Pipeline by Astellas Pharma Inc, H1 2017

Uveitis-Pipeline by Bionomics Ltd, H1 2017

Uveitis-Pipeline by Bristol-Myers Squibb Company, H1 2017

Uveitis-Pipeline by Can-Fite BioPharma Ltd, H1 2017

Uveitis-Pipeline by Clearside BioMedical Inc, H1 2017

Uveitis-Pipeline by Coherus BioSciences Inc, H1 2017

Uveitis-Pipeline by Elasmogen Ltd, H1 2017

Uveitis-Pipeline by Endocyte Inc, H1 2017

Uveitis-Pipeline by Enzo Biochem Inc, H1 2017

Uveitis-Pipeline by EyeGate Pharmaceuticals Inc, H1 2017

Uveitis-Pipeline by Eyevensys SAS, H1 2017

Uveitis-Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Uveitis-Pipeline by HanAll Biopharma Co Ltd, H1 2017

Uveitis-Pipeline by Icon Bioscience Inc, H1 2017

Uveitis-Pipeline by Idera Pharmaceuticals Inc, H1 2017

Uveitis-Pipeline by InnoMedica Holding AG, H1 2017

Uveitis-Pipeline by KPI Therapeutics Inc, H1 2017

Uveitis-Pipeline by Midatech Pharma Plc, H1 2017

Uveitis-Pipeline by Mitotech SA, H1 2017

Uveitis-Pipeline by Nemus Bioscience Inc, H1 2017

Uveitis-Pipeline by Neuroptis Biotech, H1 2017

Uveitis-Pipeline by Novartis AG, H1 2017

Uveitis-Pipeline by Oculis ehf, H1 2017

Uveitis-Pipeline by OncoNOx ApS, H1 2017

Uveitis-Pipeline by Orchid Pharma Ltd, H1 2017

Uveitis-Pipeline by OSE Immunotherapeutics, H1 2017

Uveitis-Pipeline by Palatin Technologies Inc, H1 2017

Uveitis-Pipeline by Panacea Biotec Ltd, H1 2017

Uveitis-Pipeline by Panoptes Pharma GesmbH, H1 2017

Uveitis-Pipeline by Pfizer Inc, H1 2017

Uveitis-Pipeline by pSivida Corp, H1 2017

Uveitis-Pipeline by Re-Pharm Ltd, H1 2017

Uveitis-Pipeline by Regeneron Pharmaceuticals Inc, H1 2017

Uveitis-Pipeline by Sandoz International GmbH, H1 2017

Uveitis-Pipeline by Santen Pharmaceutical Co Ltd, H1 2017

Uveitis-Pipeline by SynDevRx Inc, H1 2017

Uveitis-Pipeline by TxCell SA, H1 2017

Uveitis-Dormant Projects, H1 2017

Uveitis-Dormant Projects, H1 2017 (Contd..1), H1 2017

Uveitis-Dormant Projects, H1 2017 (Contd..2), H1 2017

Uveitis-Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

2-BBB Medicines BV, Aciont Inc, Aldeyra Therapeutics Inc, Apitope International NV, Astellas Pharma Inc, Bionomics Ltd, Bristol-Myers Squibb Company, Can-Fite BioPharma Ltd, Clearside BioMedical Inc, Coherus BioSciences Inc, Elasmogen Ltd, Endocyte Inc, Enzo Biochem Inc, EyeGate Pharmaceuticals Inc, Eyevensys SAS, F. Hoffmann-La Roche Ltd, HanAll Biopharma Co Ltd, Icon Bioscience Inc, Idera Pharmaceuticals Inc, InnoMedica Holding AG, KPI Therapeutics Inc, Midatech Pharma Plc, Mitotech SA, Nemus Bioscience Inc, Neuroptis Biotech, Novartis AG, Oculis ehf, OncoNOx ApS, Orchid Pharma Ltd, OSE Immunotherapeutics, Palatin Technologies Inc, Panacea Biotec Ltd, Panoptes Pharma GesmbH, Pfizer Inc, pSivida Corp, Re-Pharm Ltd, Regeneron Pharmaceuticals Inc, Sandoz International GmbH, Santen Pharmaceutical Co Ltd, SynDevRx Inc, TxCell SA

select a license

Single User License
USD 2000 INR 129880
Site License
USD 4000 INR 259760
Corporate User License
USD 6000 INR 389640

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com